Drug, bio-affecting and body treating compositions inventions 02/07

20070042935 - Quinazolinone-derivatives and their use for preparation of pharmaceutical compositions having parp enzyme inhibitory effect: The subject of the present invention are quinazoline derivatives and their pharmaceutically acceptable salts of general formula (I), that inhibit a DNA-repairing enzyme, poly(ADP-ribose) polymerase (PARP), enabling them to be used for the preparation of pharmaceutical compositions for preventing or treating illnesses where PARP-inhibition yields a beneficial effect. In general... Agent: Young & Thompson

20070042936 - Multivalent inhibitors of serum amyloid p component: Novel glycerol cyclic pyruvate derivates were prepared and demonstrated to inhibit the binding of an immobilized D-proline derivative to serum amyloid P component (SAP) have been prepared. As such, the compounds of the invention are useful for treating amyloidosis and diseases associated with amyloidosis, for example Alzheimer&supl;s disease and maturity... Agent: Foley & Lardner LLP

20070042937 - Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers: The present invention provides methods for increasing endogenous globin expression in a subject, specifically γ-globin expression. The invention also provides compounds and medicaments for use in the methods. The methods are particularly useful for increasing fetal hemoglobin production in a subject, and can be used to treat various disorders, e.g.,... Agent: Fibrogen, Inc. Intellectual Property Department

20070042940 - Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections: 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are... Agent: King & Spalding LLP

20070042939 - Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections: 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are... Agent: King & Spalding LLP

20070042938 - Use of dpiv and apn inhibitors for the treatment of dermatalogical diseases involving the hyperproliferation and modified differentiation conditions of fibroblasts: The invention relates to a process for the inhibition of the DNA synthesis (essential for the proliferation) of human fibroblasts by a single or joint effect of inhibitors of alanyl aminopeptidase (APN) and dipeptidyl peptidase IV (DPIV) expressed by those cells. The DNA synthesis (proliferation) of human fibroblasts is inhibited,... Agent: Hodgson Russ LLP

20070042941 - Galectin 9-inducing factors: It has been disclosed that Galectin 9, which is a physiologically active substance acting as a lectin, is expressed in various cells and a correlationship is observed between the expression level of galectin 9 and the metastatic ability of tumors. Therefore, it is presumed that galectin 9 would relate to... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070042942 - Glycopeptide carboxy-saccharide derivatives: Disclosed are glycopeptide derivatives substituted at the C-terminus and/or the R-terminus with a substituent that comprises one or more saccharide groups and a carboxy group; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.... Agent: Theravance, Inc.

20070042943 - Novel cyclosporin galenic forms: Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10.... Agent: Novartis Corporate Intellectual Property

20070042955 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Hunton & Williams LLP Intellectual Property Department

20070042961 - Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity: Variants (mutants) of recombinant activated protein C (APC) or recombinant protein C (prodrug, capable of being converted to APC) that have substantial reductions in anticoagulant activity but that retain normal levels of anti-apoptotic activity are provided. Three examples of such recombinant APC mutants are KKK191-193AAA-APC, RR229/230AA-APC, and RR229/230AA plus KKK191-193AAA-APC.... Agent: Morgan & Finnegan, L.L.P.

20070042947 - Agents for preventing and/or treating uppper digestive tract disorders: A compound or its salts that inhibit the activity of the polypeptide or receptor of the present invention and the antibody of the present invention as well as the antisense DNA of the present invention are useful as, e.g., gastric acid secretion inhibitors, mucosa protectants, mineral absorption promoters, etc., which... Agent: Edwards & Angell, LLP

20070042952 - Analogues of glp-1: Disclosed are peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, methods of using such analogues to treat mammals and pharmaceutical compositions useful therefor comprising said analogues.... Agent: Brian R Morrill Biomeasure Incorporated

20070042950 - Antagonistic analogs of gh rh (2003): There is provided a novel series of synthetic antagonistic analogs of hGH-RH(1-29)NH2. These analogs inhibit the activity of endogenous hGH-RH on the pituitary GH-RH receptors, and therefore prevent the release of growth hormone. The analogs also inhibit the proliferation of human cancers through a direct effect on the cancer cells.... Agent: Omri M. Behr

20070042953 - Antiepileptogenic complex of albumin with docosahexaenoate: The infusion of an albumin-docosahexaenoic acid (DHA) complex was shown to inhibit the progression of kindling epileptogenesis. This was shown in mice using kindling as the experimental epilepsy model. The DHA-albumin complex was shown to affect the activity of the brain when administered intraperitoneally. This therapy could also be administered... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p

20070042954 - Compositions and methods related to soluble g-protein coupled receptors (sgpcrs): The present invention is directed to compositions and methods related to soluble G-protein coupled receptors (sGPCR). In ceratin aspects the invention includes compositions and methods related to a soluble corticotropin releasing factor receptor related protein, sCRFR2, as well as its effects on CRFR signaling and interaction between CRF family ligand... Agent: Fulbright & Jaworski, L.L.P.

20070042958 - Lefty, lefty derivatives and uses thereof: The disclosure relates to Lefty derivatives and the uses of Lefty polypeptides as antagonists of the function of certain ligands such as Nodal, GDF-8 (Myostatin), and GDF-11. These derivatives may be fused to other functional heterologous proteins such as IgG, especially the Fc portion of IgG. According to the disclosure,... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070042960 - Methods of using zven proteins: The present invention provides novel uses two members of a new family of human proteins, designated as “Zven,” as agents that stimulate gastrointestinal contractility, gastric emptying, intestinal transit, and treating gastroparesis The Zven1 gene, which resides in human chromosome 3p21.1-3p14.3, is expressed in testicular tissue and peripheral blood lymphocytes. The... Agent: Zymogenetics, Inc. Intellectual Property Department

20070042945 - Nouvelles compositions et methods de traitement du psoriasis: The present invention relates to compositions and methods useful for the diagnosis and treatment of psoriasis.... Agent: Genentech, Inc.

20070042956 - Novel glp-1 compounds: Novel GLP-1 compounds and their therapeutic use.... Agent: Novo Nordisk, Inc. Patent Department

20070042946 - Peptide inhibitors of thrombin as potent anticoagulants: The tetrapeptide Phe-Asn-Pro-Arg is a structurally-optimized sequence for binding to the active site of thrombin. By conjugating this tetrapeptide or variants thereof to a C-terminal fragment of hirudin, we were able to generate a series of new multivalent inhibitors of thrombin containing only genetically encodable natural amino acids. We found... Agent: Ogilvy Renault LLP

20070042951 - Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides: Disclosed herein are dosage forms comprising an alpha-2-adrenergic agonist and a trefoil factor family peptide. Related to these dosage forms are methods of treating glaucoma or reducing intraocular pressure and methods of treating gastrointestinal disorders.... Agent: Allergan, Inc.

20070042949 - Pharmaceutical compositions comprising an epitope of platelet gpiiia protein: The present invention relates to a pharmaceutical composition for the prevention or management of a condition caused by exposure to an antithetical allele of a platelet by tolerisation, the composition comprising an immunologically effective platelet protein or peptide fragment thereof.... Agent: Licata & Tyrrell P.C.

20070042944 - Processes for the preparation of fibrinogen: The present invention relates to processes for the purification of fibrinogen, and to readily solubilised fibrinogen preparations.... Agent: Knobbe Martens Olson & Bear LLP

20070042959 - Thrombin-inhibiting peptides: Peptides of Formula I are useful for therapeutic purposes, among others.... Agent: Millen, White, Zelano & Branigan, P.C.

20070042957 - Type v phosphodiesterase inhibitors and natriuretic polypeptides: This document provides methods and materials related to PDE V inhibitors, natriuretic polypeptides, and combinations thereof. For example, compositions containing one or more PDE V inhibitors in combination with one or more natriuretic polypeptides are provided herein. In addition, methods for using PDE V inhibitors, natriuretic polypeptides, and combinations thereof... Agent: Fish & Richardson P.C.

20070042948 - Vav inhibition in graft rejection: The present invention provides a method for preventing or treating acute or chronic graft rejection in a recipient of cell, tissue or organ allo- or xenotransplant, inflammatory or autoimmune diseases or malignant proliferative disease, comprising the use of an inhibitor of Vav. Further provided are Vav inhibitors, uses, pharmaceutical compositions... Agent: Novartis Corporate Intellectual Property

20070042962 - Peptide dependent upregulation of telomerase expression: Methods and compositions comprising peptide compounds are described to upregulate expression of telomerase in eukaryotic cells, tissues, and organs. Such methods and compositions are particularly useful in treating diseases, trauma, and conditions of the aging process.... Agent: Patent Docket Administrator Lowenstein Sandler PC

20070042963 - Therapeutic peptides: The invention provides peptides of about 9-12 amino acids having a sequence derived from the interferon binding site of the IFNAR1 chain of the Type 1-interferon (Type 1-IFN) receptor for use as a Type 1-IFN antagonist. In particular, the invention provides peptides having the 9 mer sequence FSSLKLNVY (SEQ ID... Agent: Baker Botts, LLP

20070042964 - Compositions and methods for modulating connexin hemichannels: Disclosed are compositions and methods for modulating hemichannel function in a cell, tissue or organ. The invention also relates to useful screens for detecting such compounds, particularly those capable of modulating connexin phosphorylation. Further provided are therapeutic methods for preventing or treating conditions impacted by undesired hemichannel function in a... Agent: Fitzpatrick Cella Harper & Scinto

20070042965 - Crystallized structure of type iv collagen nc1 domain hexamer: The present invention provides a crystallized NC1 domain hexamer of Type IV collagen, and methods for making the crystal, wherein the NC1 domain hexamer is crystallized such that the three dimensional structure of the crystallized NC1 domain hexamer can be determined to a resolution of at least 3 Å or... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070042966 - Inhibition of cell motility, angiogenesis, and metastasis: Disclosed are methods of inhibiting cell motility, for example, by inhibiting the binding between an intracellular transducer and a receptor protein tyrosine kinase, and more particularly by inhibiting hepatocyte growth factor (HGF) induced cell motility. The present invention also provides a method of inhibiting angiogenesis. The methods of the present... Agent: Leydig, Voit & Mayer, Ltd.

20070042967 - Proteaseome inhibitors for the treatment of herpesviridae infected individuals: The present invention relates to the use of a substance or composition comprising one or more proteasome inhibitors for the manufacture of a medicament for the treatment of an individual infected with a virus selected from the group comprising varicella zoster virus, human cytomegalovirus, human herpesvirus 6 and 7 and... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070042969 - Combination therapy for pain in painful diabetic neuropathy: A method for treating pain in painful diabetic neuropathy comprises administering in combination a first agent that comprises a compound as defined herein, illustratively lacosamide, and a second agent effective to provide enhanced treatment of pain, by comparison with the first agent alone. The second agent illustratively comprises an analgesic,... Agent: Harness, Dickey, & Pierce, P.l.c

20070042968 - Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070042970 - Folate-modified cholesterol-bearing pullulan as a drug carrier: Folate modified cholesterol-bearing pullulan (FA-CHP) was synthesized by the reaction of folic acid γ-2-aminoethylamide and 4-nitorophenyl chloroformate-activated cholesterol-bearing pullulan, wherein folate and pullulan are connected through a NH—CH2—CH2—NH group. Approximately 0.5-1 folates are connected per about 100 glycoside units of pullulan. Then, several combinations of FA-CHP, cholesterol-bearing pullulan (CHP) and... Agent: Oliff & Berridge, PLC

20070042972 - Compositions and methods for optimizing exercise recovery: The present invention provides methods for decreasing post-exercise recovery time in a subject using compositions comprising one or more polymethoxylated flavones (PMFs). In preferred embodiments, the composition is an orange peel extract as described herein. In certain embodiments, post-exercise recovery time is the time for a subject's post-exercise oxygen consumption... Agent: Jones Day

20070042971 - Crystalline compound of 4'-demethyl-4'-phosphate-2\", 3\"-bispentafluorophenoxy-acetyl-4\", 6\"-ethylidene-beta-d-epipodophyllotoxin glucoside either in its free form or solvated with ethanol: The invention relates to a crystalline compound of 4′-demethyl-4′-phosphate-2″,3″-bispentafluorophenoxyacetyl-4″,6″-ethylidene-β-D-epipodophyllotoxin glucoside in its free form or solvated with ethanol, advantageously provided in the form of a hemiethanolate solvate. The invention also relates to a method for preparing these compounds and to their use as an anticancer drug.... Agent: Birch Stewart Kolasch & Birch

20070042973 - Treatment of pain and fever: This invention relates to a method of treating, decreasing, or preventing pain or fever comprising administering to a subject in need thereof a composition comprising the inventive compounds.... Agent: Nada Jain, P.C.

20070042974 - Nozel azalide and azalactam derivatives and method for producing the same: [R1 is hydrogen atom, or a linear C1-6 alkylcarbonyl group; R2 is hydrogen atom, or a C1-6 alkylcarbonyl group; R3 is hydrogen atom, a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C1-6 alkenyl group, a C2-6 alkenylcarbonyl group, a C2-6 alkynyl group, or an Ar—B— group (Ar represents an... Agent: Greenblum & Bernstein, P.L.C

20070042976 - Method of treating cosmetic and dermatologic conditions by a demethylating agent: A method for the treatment of scars and keloids is disclosed. The treatment involves an effective dose of the demethylating agents, 5-azacytidine and 2-deoxy-5-azacytidine. The method also discloses treating skin cancer with a combination therapy comprised of UV radiation and topical application or administration of the above mentioned demethylating agents.... Agent: Pearl Cohen Zedek, LLP Pearl Cohen Zedek Latzer, LLP

20070042975 - Novel indolopyrrolocarbazole derivative with antitumor activity: R2 represents a phenyl group, a naphthyl group, or a five- or six-membered aromatic or aliphatic heterocyclic ring having at least one atom selected from N, S, or O, wherein the phenyl group, naphthyl group, aromatic or aliphatic heterocyclic ring may be substituted; and G represents a hexose group or... Agent: Merck And Co., Inc

20070042985 - Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field: The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis.... Agent: Young & Thompson

20070042982 - Bioinformatically detectable group of novel regulatory bacterial and bacterial associated oligonucleotides and uses thereof: The present invention relates to a first group of novel bacterial and human associated oligonucleotides, here identified as Genomic Address Messenger or GAM oligonucleotide, and a second group of novel operon-like bacterial and human polynucleotides, here identified as Genomic Record or GR polynucleotide. GAM oligonucleotides selectively inhibit translation of known... Agent: Howrey LLP

20070042980 - Gp131: methods and compositions for treating cancer: The use of molecules relating to the GP131 (ceramide kinase) gene for treating cancer and other hyperproliferative conditions is disclosed. Non-human mammals harboring a genetic modification relating to the GP131 gene, and their use as experimental cancer models, are disclosed.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070042986 - Methods of inhibiting vegf-c: The present invention provides RNA molecules (e.g., antisense, RNAi, or siRNA) specific for VEGF-C, and further provides methods of reducing expression of VEGF-C in cells (e.g., cancer cells).... Agent: Viksnins Harris & Padys Pllp

20070042978 - Nf-hev compositions and methods of use: Aspects of the present invention relate to NF-HEV nuclear factor genes and polypeptides. Other aspects related to the use of NF-HEV nuclear factor genes and polypeptides. Other aspects related to the use of NF-HEV nuclear factor polynucleotides and polypeptides expressed in endothelial cells from chronically inflamed tissues, particularly in high... Agent: Knobbe Martens Olson & Bear LLP

20070042979 - Oligonucleic acid-bearing composite and pharmaceutical composition containing the composite: The present invention provides a complex, which comprises a cationic liposome comprising 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoylglycerol and a phospholipid as main ingredients, and an oligo nucleic acid which is carried on the liposome. Also, the present invention provides a pharmaceutical composition containing the complex to be used for treating or preventing diseases caused... Agent: Darby & Darby P.C.

20070042983 - Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating gene expression using short interfering nucleic acid (siNA) molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070042984 - Rnai modulation of the rho-a gene and uses thereof: The invention relates to compositions and methods for modulating the expression of the RhoA gene, and more particularly to the downregulation of RhoA by chemically modified oligonucleotides.... Agent: Fish & Richardson PC

20070042981 - Use of eukaryotic genes affecting chromatin separation for diagnosis and treatment of proliferative diseases: The present invention relates to the significant functional role of several C. elegans genes and of their corresponding gene products in chromatin separation during cell division that could be identified by means of RNA-mediated interference (RNAi) and to the identification and isolation of functional orthologs of said genes including all... Agent: Connolly Bove Lodge & Hutz, LLP

20070042977 - Vaccine: The invention relates to polynucleotides for DNA vaccination which polynucleotides encode an HIV envelope protein or fragment or immunogenic derivative, which is non-glycosylated when expressed in a mammalian target cell, operably linked to a heterologous promoter. Preferably the HIV envelope molecule, such as gp120 or gp140 or gp160, lacks a... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070042988 - Antiviral phosphoramidates: The invention provides novel nucleoside compounds of formula I wherein R1, R2a, R2b, R3, R4, R5, R6, R8a, R9 and R10 are as defined herein which are useful for the treatment of Hepatitis C Virus (HCV) mediated diseases. The invention further provides methods for treatment or prophylaxis of HCV mediated... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20070042989 - Novel 2'-c-methyl nucleoside derivatives: Compounds of Formula I, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral infection are described:... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070042987 - Stereoselective synthesis of beta-nucleosides: m

20070042990 - 2' and 3'-nucleoside prodrugs for treating flaviviridae infections: 2′ and 3′-Prodrugs of 1′, 2′, 3′ or 4′-branched β-D or β-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior results against flaviviruses and pestiviruses, including hepatitis C... Agent: King & Spalding LLP

20070042991 - Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections: 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are... Agent: King & Spalding LLP

20070042992 - Inulin products with improved nutritional properties: The invention relates to novel inulin products and compositions thereof, to their manufacture, to their use for modifying and modulating the bacterial flora and the fermentation pattern of inulin in the large intestine of humans, mammals or other vertebrates, to their use for providing improved inulin-associated nutritional effects/benefits, as well... Agent: Hayes, Soloway P.C.

20070042993 - Polysaccharides derivatives with high antithrombotic activity in plasma: The present invention relates to a process for the preparation of sulphated glycosaminoglycans derived from N-acetylheparosan which comprises: a) N-deacetylation and N-sulphation of the N-acetylheparosan polysaccharide prepared from natural or recombinant bacterial strain, preferably K5 E. coli, b) enzymatic epimerization with the glucuronyl C5-epimerase enzyme, c) partial O-sulphation followed by... Agent: Jay S Cinamon Abelman Frayne & Schwab

20070042994 - Pharmaceutical compositions comprising peranhydrocyclodextrin: The present invention relates to a pharmaceutical composition comprising a peranhydrocyclodextrin a drug and a carrier, to the use of a peranhydrocyclodextrin as a drug transport enhancer (e.g. permeation enhancer), and to the use of a peranhydrocyclodextrin in the preparation of a pharmaceutical composition as a synergistic adjunctive system.... Agent: Novartis Corporate Intellectual Property

20070042995 - Use of acetyl-d-aminoglycosamine in treatment of local lesions and systematic symptoms related to infections of virus or bacteria: The present invention discloses a use of N-acetyl-D-glucosamine or pharmaceutically acceptable salts thereof in the manufacture of a medicament for treating local lesions or systematic symptoms caused by infections of virus or bacteria. A parenteral preparation comprising N-acetyl-D-glucosamine or pharmaceutically acceptable salts thereof as active component is capable of controlling... Agent: Seed Intellectual Property Law Group PLLC

20070042997 - Medicament for treatment of dermal pigmentation: wherein X represents a connecting group whose number of atoms in a main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a heteroaryl group which may be substituted, ring Z... Agent: Greenblum & Bernstein, P.L.C

20070042996 - N-alkynyl-2-(substituted aryloxy) alkylthioamine derivatives as fungicides: Fungicidal compounds of the general formula (1), wherein Ar is a group of the formula (A), (B1), (B2) or (C), or Ar is a 5- or 6-linked group of the formula (D1) or (D2); and R1, R2, R3, R4, R5, n, A1, A2, A3, A4, A5, Ka, Kb, L, M,... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20070042998 - Medical cosmetic method for reducing adipose tissue and for initiating lipolysis through subcutaneous and intracutaneous injections and customized composition compounded from pharmaceutical agents for use therein: The invention describes a method and pharmaceutical compositions for subcutaneous and intracutaneous injection for reduction of localized fat deposits comprising the use of (3-sn-Phosphatidyl)-cholin as a main active and supporting ingredient either on its own, diluted or in combination with compounded agents to initiate the process of lipolysis of the... Agent: Ronald E. Greigg Greigg & Greigg P.l.l.c.

20070043000 - Immunosuppresive effects of pteridine derivatives: Novel poly-substituted pteridinediones (lumazines), and mono- or polysubstituted 2-thiolumazines, 4-thiolumazines or 2,4-dithiolumazines, having disclosed substituents in positions 1, 3, 6 and 7 of the pteridine ring, and pharmaceutically acceptable salts thereof, are useful as biologically active ingredients in preparing pharmaceutical compositions especially for the treatment or prevention of a CNS... Agent: Clark & Elbing LLP

20070042999 - Phosphate derivatives of pharmaceutical products: According to the invention, there is provided a complex of a pharmaceutical compound selected from the group consisting of opioids, hormones, anaethetics and chemotherapeutic agents comprising the reaction product of: (a) one or more phosphate derivatives of one or more opioids, steroid hormones, thyroid hormones, anaesthetics or chemotherapeutic agents having... Agent: Reed Smith LLP

20070043001 - Inhibitors of akt activity: The present invention is directed to compounds which contain a substituted pyridine moeity which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.... Agent: Merck And Co., Inc

20070043002 - Aldolase-inhibiting aromatic compounds: The invention relates to novel aldolase-inhibiting compounds that can be advantageously used as medicaments (in therapeutic doses), especially for treating certain cancers, due to the inhibition efficacy thereof. An inventive compound corresponds to general formula (I) wherein the aldehyde group (—CHO) and the phenol group (—OH) are linked to two... Agent: Clark & Elbing LLP

20070043003 - Novel compounds for the prophylaxis and treatment of inflammatory bowel diseases: Novel compounds are disclosed for the prophylaxis and treatment of inflammatory bowel disease (IBD) via the administration of an effective amount in a suitable pharmaceutical dosage of agents that are active by themselves or can deliver tin the large intestine active forms of the drugs such as 5ASA or benzoxazole... Agent: Miller, Matthias & Hull

20070043004 - High drug load mesalazine sachet: The present invention is directed to a high drug formulation having desirable properties in terms of ease of manufacture and visual appearance as well as a sachet for the formulation.... Agent: Foley And Lardner LLP Suite 500

20070043005 - Treatment of hyperproliferative diseases using high doses of active vitamin d: The present invention provides a method of inhibiting the hyperproliferative cellular activity of neoplasms and other hyperproliferative diseases with an active vitamin D compound utilizing a high dose, episodic treatment protocol.... Agent: Michael Best & Friedrich, LLP

20070043006 - Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis: Methods for the use of NSAIs in combination with anecortave acetate are disclosed for preventing and treating pathologic ocular angiogenesis and associated edema, retinal edema, PPDR or NPDR.... Agent: Teresa J Schultz Alcon Research

20070043007 - Specific glucocorticosteroid compounds having anti-inflammatory activity: t

20070043008 - Condensed bicyclo[3.1.0] hex-4-en derivatives useful as antibacterial agents: According to a first aspect of the present invention there is provided a compound of formula (I): where, A is carbon, sulphur, oxygen or nitrogen B is carbon or nitrogen, X is oxygen or sulphur, Y is hydrogen, a halogen, a substituted or unsubstituted heterocyclic moiety, substituted or unsubstituted, linear... Agent: Fish & Richardson P.C.

20070043012 - Methods to enhance chemotherapy: Antagonists of the interaction of CXCR4 receptor with its ligand enhance the effectiveness of chemotherapeutic methods in subjects afflicted with myeloid or hematopoietic malignancies.... Agent: Morrison & Foerster LLP

20070043010 - Quinazoline derivatives: The invention concerns a quinazoline derivative of the Formula (I): wherein each of the variables have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention... Agent: Morgan Lewis & Bockius LLP

20070043009 - Quinazoline derivatives as tyrosine kinase inhibitors: The invention concerns quinazoline derivatives of the Formula (I); wherein each of R1, R2, W, X1, X2, Z, a and b are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The... Agent: Morgan Lewis & Bockius LLP

20070043011 - Substituted benzanilide compound and noxious organism controlling agent:  wherein W1 and W2 each independently represent an oxygen atom or a sulfur atom, X represents a halogen atom, etc., Y represents C1 to C6 alkyl, etc., R1 represents C1 to C12 alkyl, a C1 to C6 alkylthio(C1 to C6) alkyl, a C1 to C6 alkylsulfinyl(C1 to C6) alkyl or... Agent: Manelli Denison & Selter

20070043013 - 1,3 disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases: in free or salt form, wherein Ar, X1, X2, m, R1, Q, Y, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by CCR-3, for example an inflammatory or allergic condition, particularly an inflammatory or obstructive airways disease. Pharmaceutical compositions... Agent: Novartis Corporate Intellectual Property

20070043017 - Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use: in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification. Other embodiments of the invention relate to physiologically acceptable salts of compounds of formula I, to processes for their preparation and to medicaments comprising these compounds. The compounds of the invention are suitable for... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070043018 - 2\"-hydroxynicotianamine, process for producing the same and angiotensin converting enzyme inhibitor, hypotensive drug and health food: The invention provides 2″-hydroxynicotianamine; a method for producing 2″-hydroxynicotianamine comprising the step of obtaining an extract solution from a buckwheat sample followed by obtaining a fraction having an inhibitory activity for the angiotensin-converting enzyme by ion-exchange chromatography using an anion exchange resin; novel substances having an ACE inhibitory activity by... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070043014 - 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists: The present invention encompasses compounds of Formula I: (I) as well as the pharmaceutically acceptable salts thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.... Agent: Merck And Co., Inc

20070043016 - Method of treating fibrotic diseases or other indications with imidazolium agents: e

20070043015 - Phenyl pyrrolidine ether tachykinin receptor antagonists: The present invention is directed to certain phenyl pyrrolidine ether compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their... Agent: Merck And Co., Inc

20070043019 - Salt and crystalline forms thereof of a drug: A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20070043020 - Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds: provide pharmacological agents which bind to Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the instant invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity,... Agent: Novartis Corporate Intellectual Property

20070043021 - Olanzapine analogs and methods of use thereof: The invention relates to novel compounds and methods of using them for modulating sleep.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070043022 - Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication: a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof wherein G is a direct bond or optionally substituted C1-10alkanediyl; R1 is Ar1 or a monocyclic or bicyclic heterocycle Q is R7, pyrrolidinyl substituted with R7, piperidinyl substituted with R7 or homopiperidinyl substituted with R7; one... Agent: Philip S. Johnson Johnson & Johnson

20070043023 - Modulators of muscarinic receptors: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.... Agent: Jonathan P. O'brien Miller, Canfield, Paddock And Stone

20070043024 - Azacyclic compounds as inhibitors of sensory neurone specific channels: Compounds of the formula (I), and pharmaceutically acceptable salts thereof, are found to be antagonists of SNS sodium channels. They are therefore useful as analgesic and neuroprotective agents wherein: X is —N— or —CH—; n is from 0 to 3.... Agent: Nixon & Vanderhye, PC

20070043025 - Method of treating dry eye disease with non-drying antihistamines: A method and preparation for reducing dry eye symptoms and promoting tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the eyes of the subject a non-drying antihistamine compound, such as epinastine hydrochloride, in an amount effective to reduce dry eye symptoms... Agent: Howery LLP

20070043026 - Dopamine receptor modulators as antipsychotic agents: m

20070043027 - Sulfonamide derivatives for the treatment of diabetes: The present invention is related to the use of sulfonamide derivatives in the treatment of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type II, inadequate glucose tolerance, insulin resistance, obesity, polycystic ovary syndrome (PCOS). Formula (I). R1 is selected from the group comprising or consisting of hydrogen,... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070043028 - Compositions of novel opioid compounds and method of use thereof: Diarylmethylpiperazine compounds are described, which are useful as mu and/or delta receptor opioid compounds, without central side effects. Pharmaceutical compositions containing such compounds are variously useful for peripheral or non-centrally mediated indications, including peripherally mediated and neuropathic pain, urogenital tract disorders, overactive bladder, urinary incontinence, sexual disorders, premature ejaculation, cough,... Agent: Moore & Van Allen PLLC

20070043029 - 11-phenyl-dibenzodiazepine derivatives as rxr-antagonists: The present invention relates to novel benzodiazepine compounds exhibiting RXR-antagonist efficacy, for delaying progression of, preventing or treating a condition or disease being associated with RXR-antagonism, in particular selected from diabetes, complication of diabetes such as retinopathy, nephropathy, neuropathy, and hyperlipidemia, obesity, dyslipidemia, and osteoporosis.... Agent: Novartis Corporate Intellectual Property

20070043034 - Chlorine ion uptake modulators and uses thereof: The present invention provides methods for using chloride ion uptake modulators to treat disorders that are mediated by a sodium/potassium/chloride cotransporter.... Agent: Faegre & Benson LLP Patent Docketing

20070043032 - Composition comprising a benzodiazepine agonist and a benzodiazepine antagonist: A composition comprising a benzodiazepine agonist, a benzodiazepine antagonist, and a pharmaceutical acceptable carrier in an effective ratio so as to preserve the therapeutic effects of the benzodiazepine agonist while modulating the side effects of the benzodiazepine agonist.... Agent: The Bilicki Law Firm, PC

20070043031 - Non-amide nonanes: and pharmaceutically-acceptable salts thereof, wherein Q, E and D are as defined in the specification, enantiomers, in vivo-hydrolysable precursors, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070043030 - Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation: The present invention relates to improved formulations for the treatment of premature ejaculation and, in particular, relates to the administration of antidepressants by pulmonary inhalation for treating premature ejaculation. Various types of known antidepressants may be used, including tricyclic antidepressants, such as clomipramine.... Agent: Davidson, Davidson & Kappel, LLC

20070043033 - Unsolvated benzodiazepine compositions and methods: The present invention relates to systems and methods for generating new forms of benzodiazepine and benzodiazepine related compounds as well as new compounds and formulations generated by such methods. In particular, the present invention provides high throughput systems and methods for generating and identifying new crystalline benzodiazepine and benzodiazepine related... Agent: Medlen & Carroll, LLP

20070043035 - Novel compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them: The present invention relates to novel hypolipidemic, antiobesity, hypocholesterolemic and antidiabetic compounds. More particularly, the present invention relates to novel alkyl carboxylic acids of the general formula (I), their stereoisomers, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing them where all symbols are as defined in the description.... Agent: Milagros A. Cepeda Dr. Reddy's Laboratories, Inc.

20070043036 - 2-pyridone derivatives as neutrophil elastase inhibitors and their use: There are provided novel compounds of formula (I), wherein R1, R2, R4, R5, G1, G2, L, Y and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in... Agent: Morgan Lewis & Bockius LLP

20070043037 - Pyrimidine derivatives as orexin receptor antagonists: The present invention relates to the orexin receptor antagonists of the general formula (I), which are selective to orexin I receptors.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070043038 - Indolone-acetamide derivatives, processes for preparing them and their uses: The present invention relates to indolone-acetamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as for the treatment of epilepsy, epileptogenesis, seizure disorders and convulsion.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070043039 - Substituted quinobenzoxazine analogs: e

20070043043 - Benzimidazole derivates: preparation and pharmaceutical applications: The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to benzimidazole containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or... Agent: Connolly Bove Lodge & Hutz LLP

20070043041 - Indol-6 sulfonamide derivative, their preparation and their use 5-ht-6 as modulators: The present invention refers to new sulfonamide derivatives, of general formula (la, lb, lc) optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate, or in form of a mixture of at least two of their stereoisomers, preferably enantiomers or diastereomers, at any mixing ratio or... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070043040 - Inhibitors of akt (protein kinase b): The present invention relates to compounds Formula (I): as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.... Agent: Eli Lilly & Company

20070043042 - Quinoline potassium channel inhibitors: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.... Agent: Merck And Co., Inc

20070043044 - Pyrimidothiophene compounds: Compounds of formula (1) are inhibitors of HSP90 activity in vitro or in vivo, and of use in the treatment of inter alia, cancer wherein R2 is a group of formula —(Ar1)m-(Alk1)P-(Z)r-(Alk2)S-Q wherein Ar1 is an optionally substituted aryl or heteroaryl radical, Alk′ and Alk 2 are optionally substituted divalent... Agent: Banner & Witcoff

20070043045 - Novel high affinity thiophene-based and furan-based kinase ligands: Inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070043046 - Biaromatic ligand activators of ppargamma receptors: h

20070043047 - Fungicidal mixtures for controlling rice pathogens:

20070043048 - 2-aminopyrimidine derivatives and their medical use: A compound of formula I or a pharmaceutically acceptable salt, ester or prodrug thereof wherein the variables have the meanings as defined in the specification. Further disclosed are a method of inhibiting IKK activity using a compound of formula I, a method of inhibiting production of TNF using a compound... Agent: Novartis Corporate Intellectual Property

20070043051 - Methods and compositions of novel triazine compounds: The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that... Agent: Womble Carlyle Sandridge & Rice, PLLC

20070043050 - Sirtuin modulating compounds: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases,... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070043049 - Substituted heterocyclic diarylamine analogues: Substituted heterocyclic diarylamine analogues of Formula I are provided: wherein X, Y and Z are independently N or optionally substituted C, and other variables are as described in the specification. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are... Agent: Edwards & Angell, LLP

20070043053 - Pyrrolo-triazine aniline compounds useful as kinase inhibitors: b

20070043052 - Reverse-turn mimetics and method relating thereto: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed... Agent: Seed Intellectual Property Law Group PLLC

20070043055 - Dihydropteridinones in the treatment of respiratory diseases: n

20070043054 - Enzyme cofactor combination for supplementing pyruvate dehydrogenase and alpha ketogluterate dehydrogenase complexes: The present invention provides a method and pharmaceutical composition for preventing or treating the development of syndromes related to dysfunctional energy metabolism, such as neuropathy, spontaneous nocturnal muscle cramps associated with neuropathy, seizuring, diabetes mellitus; pediatric hypoglycemia; myopathy; muscle fatigue; muscle spasms; somnolence; reduced mental acuity; exercise intolerance and myocardial... Agent: The Webb Law Firm, P.C.

20070043057 - Lonidamine analogs: Lonidamine analogs are useful in the treatment and prevention of cancer, benign prostatic hyperplasia, macular degeneration and prostatic intraepithelial neoplasia, or for use as an antispermatigenic agent.... Agent: Townsend And Townsend And Crew, LLP

20070043056 - 5-substituted-2-arylpyrazines: Novel 5-substituted-2-arylpyrazine compounds are provided. Such compounds can act as selective modulators of CRF receptors. The 5-substituted-2-arylpyrazine compounds provided herein are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well... Agent: Edwards & Angell, LLP

20070043058 - Novel 2,3-dihydroindole compounds: v

20070043059 - N-oxides as prodrugs of piperazine and piperidine derivatives:

20070043060 - Oxazole derivatives, preparation and therapeutic use thereof:

20070043063 - Azaindoles useful as inhibitors of jak and other protein kinases: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Karen Brown Vertex Pharmaceuticals Incorporated

20070043061 - Furazanobenzimidazoles: The invention relates to compounds of formula (I) wherein R represents aryl or heteroaryl, X is oxygen, a carbonyl group, an oxime derivative of a carbonyl group or an α,β-unsaturated carbonyl group, and the substituents R1 to R6 have the meanings given in the specification, for use as medicaments, to... Agent: Gibbons, Del Deo, Dolan, Griffinger & Vecchione

20070043062 - Isoxazoles as peptide deformylase inhibitors: Isoxazole compounds of formula (I) and pharmaceutically acceptable salts or esters thereof are peptide deformylase inhibitors useful in the treatment or prevention of infections and other disease in which peptide deformylases are involved, especially in the treatment of bacterial and parasitic infections, for example infections fully or partly caused by... Agent: Edwards & Angell, LLP

20070043064 - 7-substituted 3-nitro-pyrazo[1,5-a] pyrimidines: The present invention relates to compounds of Formula (I): wherein R1 is as defined in the claims. The compounds have specific affinity for the GABAA receptor and are therefore useful in the treatment and prevention of diseases modulated by the α1- and α2-GABAA receptors.... Agent: Birch Stewart Kolasch & Birch

20070043065 - Amide derivatives: The invention concerns a compound of the Formula (I) wherein m is 0-2 and each R1 is a group such as hydroxy, halogeno, trifluoromethyl heterocyclyl and heterocyclyloxy; R2 is halogeno, trifluoromethyl or (1-6C)alkyl; R3 is hydrogen, halogeno or (1-6C)alkyl; and R4 is (3-6C)cycloalkyl; or pharmaceutically-acceptable salts thereof; processes for their... Agent: Morgan Lewis & Bockius LLP

20070043066 - Glutamate aggrecanase inhibitors: The present invention relates to modulators of metalloproteinase activity.... Agent: Wilmerhale/wyeth

20070043067 - 7-polyaminoalkyl(oxy)iminomethylcamptothecins bearing protective groups: in which the groups are as defined in the description here below and characterized by the presence of polyamine substituents on the imine/oxime residue, such amine groups being in turn protected by suitable protective groups. Said compounds are endowed with potent topoisomerase I inhibiting activity and therefore are useful as... Agent: Nixon & Vanderhye, PC

20070043069 - Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase:

20070043068 - Pyrrolo-pyridine kinase modulators: The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity.... Agent: Townsend And Townsend And Crew, LLP

20070043072 - Aminopyridine-derivatives as inductible no-synthase inhibitors: e

20070043071 - Further therapeutic use of zolpidem: An imidazo[1,2-a]pyridine-3-acetamide such as zolpidem is useful in the treatment of a condition of the brain which has a lesion and exhibits diaschisis/dormant cells at the contralateral and other sites, more particularly trauma-induced injury, spinocerebellar ataxia, cerebellar or cerebral infarct and Ramsey-Hunt syndrome.... Agent: Rankin, Hill, Porter & Clark, LLP

20070043073 - Imidazopyridine-derivatives as inductible no-synthase inhibitors:

20070043074 - Imidazo[1,2-a] pyridine anxiolytics:

20070043070 - Weak base salts: Pharmaceutical compositions comprising a salt of a weak base compound of formula: wherein X is hydrogen, halogen, alkyl of less than 7 carbon atoms or alkoxy of less than 7 carbon atoms; n is a positive integer of less than 4; Y is hydrogen, chlorine, nitro, methyl, ethyl or oxy-chloro;... Agent: Greenlee Winner And Sullivan P C

20070043075 - 2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane tartrate salts: This invention relates to novel (1R,2R,3S,5S)-2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane tartrate salts, such as L-tartrate monohydrates and anhydrates. The salts are useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these salts in a method for therapy and to pharmaceutical compositions comprising the salts of the invention.... Agent: Birch Stewart Kolasch & Birch

20070043076 - Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis: The present invention is directed to substituted 2-arylmethylene-N-aryl-N′-aryl-malonamides and analogs thereof. The present invention also relates to the discovery that the compounds are activators of caspases and inducers of apoptosis. Therefore, the activators os caspases and inducers of apoptosis of this invention can be used to induce cell death in... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070043077 - Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents: e

20070043078 - Angiogenesis inhibitor: wherein R1, R2, and R3 each independently represent a hydrogen atom, a halogen atom, a hydroxy group, an alkyl group, a halogen-substituted alkyl group, an alkoxy group, an alkylthio group, a carboxyl group, an alkoxycarbonyl group, or an alkanoyl group; W1 and W2 each independently represent N or CH; X... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070043079 - Heterocyclic compound containing nitrogen atom and use thereof: wherein all symbols have the same meanings as defined in the specification, a salt thereof or a prodrug thereof. The compound of the present invention is useful for the prevention and/or treatment of immune diseases such as various types of inflammation, autoimmune disease, allergic diseases, etc.; infection concerning inflammation or... Agent: Sughrue-265550

20070043080 - Substituted anilinic piperidines as mch selective antagonists: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20070043081 - Novel pyridine derivatives: The invention relates to novel pyridine derivatives and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as... Agent: Dickstein Shapiro LLP

20070043082 - Use of antimuscarinic drugs: The use of antimuscarinic drugs, biperiden in special, as a medication for preventing the onset of epilepsy that might ensure after the condition of status epileticus, major head trauma, including those occasioned by neurosurgical trauma, and acute lesional events to the brain.... Agent: Thomas A. O'rourke Bodner & O'rourke, LLP

20070043083 - Thiazolyl piperidine derivatives: wherein R1, R2 and R3 are as defined in the description and claims. It further relates to pharmaceutically acceptable salts thereof as well as to pharmaceutical compositions comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070043084 - 1,2-diarylimidazoles useful as inhibitors of cox: A compound of the formula (1): wherein R1 is cyano, and the like; R2 is hydroxy, and the like; R3 is (lower)alkoxy, and the like; X and Y are each CH or N; or pharmaceutically acceptable salts thereof, which are useful as a medicament.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070043085 - Process for the preparation of amorphous form of neutral esomeprazole: A process for preparing neutral esomeprazole in an amorphous form is provided comprising (a) providing an aqueous solution comprising a salt of esomeprazole; (b) neutralizing the solution with a neutralization agent to provide a neutralized solution; (c) contacting the neutralized solution with an extracting solvent; and (d) recovering the neutral... Agent: M. Carmen & Associates, PLLC

20070043086 - Agents for controlling plant pests: p

20070043087 - Compounds exhibiting thrombopoietin receptor agonism: wherein R1 is a hydrogen atom, a halogen atom, or the like; R2, R3, and R4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R5 is a hydrogen atom or the like; R6... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070043088 - Process for preparing lacidipine: A process for preparing lacidipine, comprising reacting a t-butoxy carbonyl methyl aryl phosphonium halide with o-phthalaldehyde, and further reacting a product comprising (E)-3-(2-formylphenyl)-2-propenoic acid, 1,1-dimethyl ethyl ester, without isolation, with ethyl-3-amino crotonate.... Agent: Dr. Reddy's Laboratories, Inc.

20070043089 - Method of inhibiting angiogenesis: p

20070043091 - Kv1.5-blocker for the selective increase of atrial contractility and treatment of cardiac insufficiency:

20070043090 - Novel sulfonamides: R4 and R5 are independently selected from the group consisting of H, C1-C10 alkyl, C1-C10 alkyl hydroxyl; m is 0 or an integer from 1 to 3 and n is an integer of from 1 to 4. These compounds are useful in lowering intraocular pressure and/or treating glaucoma or providing... Agent: Allergan, Inc.

20070043092 - Use of aryl hydrocarbon receptor ligand as a therapeutic intervention in angiogenesis-implicated disorders: A method of treating angiogenesis-implicated disorders by selecting a subject predisposed to an angiogenesis-implicated disorder and then administering an effective amount of an endogenous aryl hydrocarbon receptor ligand or its analogs according to a formula as disclosed herein is disclosed.... Agent: Quarles & Brady LLP

20070043093 - Glucagon-like peptide-1 receptor agonists, the preparation and the use of the same: The present invention provides the glucagon-like peptide-1 receptor agonists. It is indicated that the agonists have good binding capability to glucagon-like peptide-1 receptor by pharmacological tests. The present invention also provides the preparation of the agonists.... Agent: Baker & Hostetler LLP

20070043094 - Pioglitazone hydrochloride: Provided is a novel crystal form of pioglitazone hydrochloride and a method for making it. Also provided is a method for making a known crystal form of pioglitazone hydrochloride.... Agent: Kenyon & Kenyon LLP

20070043095 - Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use: o

20070043097 - Medicaments containing famotidine and ibuprofen and administration of same: A method for administration of ibuprofen to a subject in need of ibuprofen treatment is provided, in which an oral dosage form comprising a therapeutically effective amount of ibuprofen and a therapeutically effective amount of famotidine, in admixture, is administered three times per day.... Agent: Townsend And Townsend And Crew, LLP

20070043096 - Unit dose form with ibuprofen-famotidine admixture: An oral dosage form for administration of ibuprofen to a subject in need of ibuprofen treatment is provided, in which an oral dosage form comprising a therapeutically effective amount of ibuprofen and a therapeutically effective amount of famotidine, in admixture, in amounts suitable for three times per day administration.... Agent: Townsend And Townsend And Crew, LLP

20070043098 - Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides: The present invention relates to a method for preparing substituted tetrazoles, compounds obtained according to this method, new reactants and new tetrazole derivatives.... Agent: Novartis Corporate Intellectual Property

20070043099 - Crystalline forms of carvedilol and processes for their preparation: This invention relates to a novel crystalline form of carvedilol, to processes for its preparation, to compositions containing it and to its use in medicine. This invention further relates to a novel process for preparing crystalline carvedilol Form II.... Agent: Kenyon & Kenyon LLP

20070043100 - Novel polymorphs of azabicyclohexane: The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph... Agent: Graybeal, Jackson, Haley LLP

20070043101 - Substituted indoles and methods of their use: The present invention relates generally to substituted indoles and methods of using them.... Agent: Woodcock Washburn LLP

20070043103 - Novel metod for the synthesis of perindopril and the pharmaceutically-acceptable salts thereof: e

20070043102 - Oral suspension of tegaserod: This invention relates to an oral suspension of tegaserod or pharmaceutically acceptable salts thereof. In particular, it relates to an oral suspension comprising a power comprising an effective amount otegaserod or a pharmaceutically acceptable salt thereof in a beverage, e.g. apple juice.... Agent: Novartis Corporate Intellectual Property

20070043104 - Uii-modulating compounds and their use: Disclosed herein are novel aromatic-containing compounds and methods for using various aromatic-containing compounds for treatment and prevention of diseases and disorders related to the Urotensin II receptor.... Agent: Knobbe Martens Olson & Bear LLP

20070043105 - Preventive for cerebal stroke recurrence: The invention provides a novel cerebral stroke recurrence inhibitor, and relates to a simple evaluation method for an cerebral stroke recurrence inhibitor. According to the simple evaluation method using stroke-prone spontaneously hypertensive (SHR-SP) rats, which has been established by the present inventors, it has been confirmed that atorvastatin is effective... Agent: Sughrue-265550

20070043106 - Alpha-lipoic acid concentrate: A water-free concentrate, consisting of ubichinon Q10, a medium-chained triglyceride or triglyceride mixture, α-lipoic acid and/or its derivative as well as one or more emulgators with HLB value between 9 and 19 permitted according to the foodstuff or drug laws has been described.... Agent: Jacobson Holman PLLC

20070043107 - Processes for preparing alkyl 3-(4-tetrahydropyranyl)-3-oxopropanoate compound and 4-acyltetrahydropyrane: w

20070043108 - Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders: The invention is directed to a method of preventing or ameliorating a neuropsychiatric or neurodegenerative disease or disorder in a subject. The method includes administering a composition comprising equol in an amount sufficient to prevent or ameliorate the neuropsychiatric or neurodegenerative disease or disorder. The equol may be a racemic... Agent: Brinks Hofer Gilson & Lione

20070043109 - Slimming cosmetic composition: Cosmetic or dermopharmaceutical compositions containing, in a dermatologically acceptable carrier, at least one diterpene among: cafestol, kahweol and chemical derivatives are useful for slimming treatments including prevent and/or treat cellulite or orange peel and/or to refine contours of the face, skin firming, to reduce the steatomery of the thighs, to... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070043110 - Nontoxic potentiation sensitization of ovarian cancer therapy by supplementary treatment with vitamins: A combination of Vitamin C and a quinone used as a supplemental treatment for an ovarian cancer patient. The combination may be administered before, during and after the patient undergoes a conventional cancer treatment protocol. The combination may be administered orally, intravenously, or intraperitoneally. Oral administration may be in the... Agent: Brouse Mcdowell Lpa

20070043111 - Use of ifenprodril in the treatment of pain: Ifenprodil is useful for the treatment of pain.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070043112 - Use of non-opiates for the potentation of opiates: A non-opioid analgesic is used for the treatment of intermittent or episodic pain experienced by a patient undergoing chronic pain treatment with an opioid analgesic.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070043113 - Novel compounds: The present invention relates to novel phenylalanine compounds, processes for their preparation, compositions comprising them and their use in the treatment or prevention of diseases capable of being modulated by the inhibition of cell adhesion.... Agent: Birch Stewart Kolasch & Birch

20070043114 - Nerve regeneration promoters: (wherein all symbols are shown in the description), a salt thereof or a prodrug thereof. The compound of the present invention is suppresses nerve cell death as a substance for accelerating growth and/or differentiation of stem cells (nerve stem cells, embryonic stem cells, bone marrow cells, etc.), a substance for... Agent: Sughrue-265550

20070043115 - Use of choline to prevent thrombosis associated with total parenteral nutrition: Choline deficiency is a risk factor for the development of thrombosis in patients with intestinal failure that require total parenteral nutrition. There is provided a method of preventing thrombosis, preferably venous thrombosis, comprising administering to a patient receiving TPN a nutrient solution comprising choline. Also provided is a method of... Agent: Mcdermott Will & Emery LLP

20070043116 - Method for preventing and/or treating neurodegenerative diseases: The invention relates to a neurodegenerative disease treating agent for parenteral use, which comprises (2R)-2-propyloctanoic acid or a salt thereof. Since the neurodegenerative disease treating agent of the present invention comprising (2R)-2-propyloctanoic acid or a salt thereof, characterized in that a dosage exceeding about 100 mg per dose is parenterally... Agent: Sughrue-265550

20070043117 - Process for the preparation of chirally pure n-(trans-4-is: The invention relates to N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine (nateglinide) in the novel crystalline form “G” and a process for the preparation thereof. A process for the preparation of chirally pure nateglinide by treating a lower alkyl ester thereof with a base to yield an alkali salt and liberating the product from said salt... Agent: The Firm Of Karl F Ross

20070043118 - Method of treating a subject suffering from degenerative disc disease using a nitric oxide synthase inhibitor: The present invention provides a method for treating a vertebrate subject suffering from a degenerative disc disease by administering an inhibitor of nitric oxide synthase (NOS) to the subject in an amount effective to treat the subject.... Agent: Cooper & Dunham, LLP

20070043119 - Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders: Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions.... Agent: Buchanan Ingersoll And Rooney PC

20070043120 - Therapeutic combination for painful medical conditions: A therapeutic combination comprises a first agent comprising a compound as defined herein, illustratively lacosamide, or a pharmaceutically acceptable salt thereof, and a second agent effective in combination therewith to (a) provide enhanced treatment of pain associated with or caused by a medical condition, by comparison with the first agent... Agent: Harness, Dickey, & Pierce, P.l.c

20070043121 - Discovery of novel soluble crystalline anesthetics: The invention discloses compounds derived from propofal which have greater aqueous solubility than propofal and are useful as anesthetic agents. The invention further discloses methods of preparing compounds of the invention. The invention also discloses methods of inducing anesthesia in a subject by administering compounds of the invention to the... Agent: University Of Virginia Patent Foundation

20070043122 - Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders: The invention relates to the use of 2,2,3,3 tetramethylcyclopropane carboxylic acid derivative compounds for the preparation of a medicament for treating a psychiatric disorder preferably a bipolar disorder. The invention additionally relates to the use of the compounds for the preparation of an inhibitor of MIP synthase and to a... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070037734 - Process for the purification of il-18 binding protein: The invention relates to a process for the purification of IL-18 binding protein (IL-18BP) from a fluid comprising hydrophobic charge-induction chromatography.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070037735 - 2' and 3'-nucleoside prodrugs for treating flaviviridae infections: 2′ and 3′-Prodrugs of 1′, 2′, 3′ or 4′-branched β-D or β-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior results against flaviviruses and pestiviruses, including hepatitis C... Agent: King & Spalding LLP

20070037737 - Composition and method for the repair and regeneration of cartilage and other tissues: The present invention relates to a new method for repairing human or animal tissues such as cartilage, meniscus, ligament, tendon, bone, skin, cornea, periodontal tissues, abscesses, resected tumors, and ulcers. The method comprises the step of introducing into the tissue a temperature-dependent polymer gel composition such that the composition adhere... Agent: David S. Resnick

20070037736 - Therapeutic composition comprising the kal protein and use of the kal protein for the treatment of retinal, renal, neuronal and neural injury: KAL protein is identified the active agent in a therapeutic composition for treatment of injury to nerve tissue, including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein.... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070037738 - Using inhibitors of histone deacetylases for the suppression therapy of inherited disease predisposing conditions: Compounds can be used to act as inhibitors of enzymes having histone deacetylase activity for the medical therapy of conditions which predispose a person for the development of a disease, such as but not limited to cancer, inflammatory or metabolic diseases. Such conditions are linked to genetically inherited mutations of... Agent: Cermak & Kenealy LLP

20070037740 - Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis: The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of alphacalcidol, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple... Agent: Cooper & Dunham, LLP

20070037739 - Compounds useful in coating stents to prevent and treat stenosis and restenosis: At least one bioactive agent is locally delivered to a location where a stent is implanted within a lumen in a patient's body. The bioactive agent includes a: DNA minor groove binder (such as CC-1065 or Duocarmycin); apocynin; RGD peptide (such as RGDfV); stilbene compound (such as resveratrol); camptothecin; des-aspartate... Agent: Preston Gates & Ellis LLP Attn: C. Rachal Winger

20070037747 - Exendin 4 polypeptide fragment: The present invention relates to an Exendin 4 polypeptide fragment, which has hypoglycemic activity, and can be used for the treatment of type II diabetes mellitus. The polypeptide sequence described herein is HGEGTX1TSDLSKQX2EEEAVX3LFIEWLKNGX4PX5, where X1 represents Phe or Tyr, X2 represents Met, Ile or Leu, X3 represents Lys, X4 represents... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20070037744 - Human cathelicidin antimicrobial peptides: Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.... Agent: Buchanan, Ingersoll & Rooney LLP

20070037750 - Methods for glucagon suppression using modified exendins: Methods for use of an exendin, an exendin agonist, or a modified exendin or exendin agonist having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, for lowering glucagon levels and/or suppressing glucagon secretion in a subject are provided. These methods are are useful... Agent: Arnold & Porter LLP (18528) Attn IPDocketing Dept.

20070037748 - Methods of treating diseases with a vegf antagonist: A method of reducing or preventing hypertension associated with administration of a vascular endothelial growth factor (VEGF) antagonist in a human subjects suffering from a disease or condition treatable with a VEGF antagonist in which is it desirable to reduce or prevent hypertension. The method is particularly useful for treatment... Agent: Regeneron Pharmaceuticals, Inc

20070037741 -